All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company.
This website contains “forward-looking statements” with the meaning of the Private Securities Litigation Reform Act of 1995. Any statements on this website about future expectations, plans and prospects for Trevena, including statements about the Trevena’s strategy, future operations, clinical development of its therapeutic candidates, plans for potential future product candidates and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, are intended to identify forward-looking statements. These forward-looking statements reflect Trevena’s plans, objectives, estimates, expectations and intentions only as of the date of the document containing the forward-looking statement or as of the dates indicated in the forward-looking statements, and inherently involve significant risks and uncertainties. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Many of these risks and uncertainties are described under the caption “Risk Factors” and elsewhere in Trevena’s Securities and Exchange Commission filings and reports, including in Trevena’s most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q or in other filings or documents Trevena makes with the SEC from time-to-time.